"Respectfully I don't agree. I'm in PTX as well as CHM but the...

"Respectfully I don't agree. I'm in PTX as well as CHM but the Omnicar platform is a CAR-T therapy variant. Instead of treating T-cells with the 'warhead' then returning to the patient, Omnicar is instead an implantation of a 'velcro-like' protein that then allows a 'warhead' be attached thereafter. Pros and cons to both but CAR-T is tried, tested, established and demonstrating phenomenal results (look at multiple myeloma). Omnicar has literally only just chosen their 3 path strategy (on the day of CHM's float... ) whilst CHM is quite literally treating patients already trying to find their optimal dose. The existing clinical use of CHM's chimeric antigen in non-CAR-T therapy is a credit to its susceptibility to latch on the cancers we'll be targeting.Happy to corrected to the above but the price disparity is not a comparison between apples. They both work on bioengineering patient's T cells and the similarity stops there. CHM is significantly more advanced in their development pipeline already, though this is not to discredit PTX.Please don't accept this as cross-advertisement - everyone here is comparing PTX to CHM and the recent rise in PTX's value through CHM's float alone is proof of this. Whilst I hope it's increasing awareness to the only ASX companies in the 'T-cell' space (if you can liken them both), I think it's misinformation that one is simply a cheaper stock than the other. Stoked to be in on Paul Hooper's and Leslie Chong's new child!"

whoops quote didnt work on last one, see above in quotations